GNH USA

Europe — EMA

Normosang (Human Hemin)

GNH USA supplies Normosang (Human Hemin), a heme preparation for acute intermittent porphyria and other acute hepatic porphyria attacks.

Human Hemin

Request sourcing

1
Pack/s

What is Human Hemin?

Human Hemin, the active ingredient in Normosang, is a heme preparation presented as an injectable solution (lyophilized powder for reconstitution) for intravenous use. It treats acute intermittent porphyria and other acute hepatic porphyria attacks in patients experiencing an acute episode.

GNH USA supplies Normosang as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

What is Human Hemin used for?

Normosang is a heme preparation used to manage acute porphyria attacks by restoring feedback inhibition in the heme biosynthetic pathway.

Acute intermittent porphyria: reduces neurotoxic porphyrin precursor accumulation and helps terminate the attack. Other acute hepatic porphyria attacks: decreases symptom severity and shortens attack duration. Acute porphyria crises: provides rapid clinical improvement and stabilises metabolic disturbances.

What are the side effects of Human Hemin?

Normosang may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion site pain or erythema - Nausea or vomiting - Fever or chills - Headache - Mild hypotension - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reaction - Hemolysis leading to anemia - Acute renal impairment or failure - Thrombophlebitis at the infusion site - Severe hypotension or shock

What precautions apply to Human Hemin?

When using Normosang, clinicians should observe several safety measures.

Monitor liver function: assess hepatic enzymes before and during therapy. Assess iron status: avoid in patients with known iron overload. Check for hypersensitivity: discontinue immediately if severe allergic signs appear. Use with caution in renal impairment: increase monitoring of renal parameters. Avoid in patients with active infection unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Human Hemin interact with?

Human Hemin can interact with certain drugs and substances that affect porphyrin metabolism.

Major Interactions (Avoid): - Concurrent use of porphyrinogenic drugs (e.g., certain anticonvulsants) may exacerbate porphyria. - Iron chelators such as deferoxamine may reduce hemin efficacy.

Moderate Interactions (Monitor Closely): - Anticonvulsants like barbiturates: may increase porphyrin precursor levels. - Hormonal contraceptives: can trigger porphyria attacks. - Alcohol consumption: may worsen porphyria symptoms.

Frequently asked questions

What is Normosang used for?+
Normosang is a prescription heme preparation containing human hemin, indicated for the treatment of acute intermittent porphyria and other acute hepatic porphyria attacks. It is administered intravenously to help terminate an acute porphyria crisis by reducing the buildup of toxic porphyrin precursors.
How does Human Hemin work?+
Human hemin supplies exogenous heme, which restores the normal feedback inhibition of the enzyme aminolevulinic acid synthase (ALAS) in the hepatic heme biosynthetic pathway. By suppressing ALAS activity, it decreases the production of aminolevulinic acid and porphobilinogen, limiting accumulation of neurotoxic intermediates that cause symptoms during an acute porphyria attack.
What is the usual dose of Normosang?+
The dosing regimen for Normosang is individualized and determined by the prescribing physician based on the severity of the acute porphyria episode, patient weight, and clinical response. The product is supplied as a lyophilized powder for reconstitution and must be administered intravenously under medical supervision.
Is Normosang safe in pregnancy or breastfeeding?+
Safety data for human hemin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or breastfeeding should only occur if the potential benefit justifies the potential risk to the fetus or infant, and it must be decided by the treating clinician.
How do I order Normosang from GNH USA?+
To place an order, submit an inquiry on the product page at gnh-usa.com specifying the required quantity of Normosang. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.
How does Normosang compare with other porphyria treatments?+
The primary alternative to human hemin is the use of glucose loading, which can suppress ALAS activity but is less rapid and less effective in severe attacks. Other heme preparations, such as hemin arginate, have similar mechanisms. Normosang provides a standardized, injectable heme source with established efficacy for quickly terminating acute porphyria crises.
What are the storage requirements for Normosang?+
Normosang must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the reconstituted solution. Proper cold‑chain storage maintains product stability and potency until the point of use.
How is Normosang administered?+
Normosang is supplied as a lyophilized powder that is reconstituted with the appropriate diluent immediately before use. The resulting solution is administered intravenously, typically through a peripheral or central line, under the supervision of qualified healthcare professionals. Infusion rates and monitoring are guided by the prescribing physician’s protocol.
What are the most serious risks to watch for?+
Serious adverse reactions, although rare, include anaphylaxis, severe hemolysis, renal impairment, and thrombophlebitis at the infusion site. Patients should be monitored closely for signs of hypersensitivity, sudden drop in hemoglobin, kidney function changes, or vascular complications during and after the infusion.
Who should not use Normosang?+
Normosang is contraindicated in patients with known hypersensitivity to human hemin or any component of the formulation. Caution is advised in individuals with severe iron overload, uncontrolled renal failure, or active infection, and it should be avoided in patients for whom alternative, non‑heme therapies are appropriate unless specifically indicated by a physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Hemin
Route
Intravenous Use
Manufacturer
Recordati Rare Diseases
Origin
EU

Related products

Human Hemin Orphan Europe

Human Hemin Orphan Europe

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Orphan Europe Sarl
EU